Ascendis Pharma A/S (NASDAQ:ASND) price target dropped to $170.00 at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND – Free Report) The price objective was reduced by Cantor Fitzgerald from $173.00 to $170.00 in a report issued on Wednesday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

ASND has been the subject of a number of other reports. Jefferies Financial Group lifted their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a buy rating in a research note on Tuesday, August 13th. StockNews.com cut shares of Ascendis Pharma A/S from a hold rating to a sell rating in a research note on Tuesday, August 13th. JPMorgan Chase & Co. lifted their price objective on shares of Ascendis Pharma A/S from $170.00 to $174.00 and gave the company an overweight rating in a research note on Wednesday, August 21st. Morgan Stanley boosted their target price on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an equal weight rating in a research report on Thursday, May 16th. Finally, Evercore ISI raised shares of Ascendis Pharma A/S to a strong-buy rating in a report on Monday, August 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Ascendis Pharma A/S has an average rating of Moderate Buy and a consensus price target of $188.09, based on data from MarketBeat.

Check out our latest research report on Ascendis Pharma A/S

Ascendis Pharma A/S trading down 11.3%

Shares of ASND opened at $119.50 on Wednesday. The stock’s 50-day moving average is $135.06, and its two-hundred-day moving average is $138.60. Ascendis Pharma A/S has a 12-month low of $85.29 and a 12-month high of $161.00. The firm has a market cap of $6.96 billion, a PE ratio of -12.43 and a beta of 0.63.

Institutional trading of Ascendis Pharma A/S

Several large investors have recently bought and sold shares of ASND. Quarry LP lifted its position in shares of Ascendis Pharma A/S by 257.1% in the second quarter. Quarry LP now owns 2,500 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 1,800 shares in the last quarter. Algert Global LLC raised its stake in Ascendis Pharma A/S by 54.6% in the second quarter. Algert Global LLC now owns 2,180 shares of the biotechnology company’s stock worth $297,000 after buying an additional 770 shares during the period. Lighthouse Investment Partners LLC purchased a new position in Ascendis Pharma A/S in the second quarter valued at $2,762,000. Fred Alger Management LLC boosted its position in Ascendis Pharma A/S by 65.0% in the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after buying an additional 120,952 shares in the last quarter. Finally, First Light Asset Management LLC purchased a new position in Ascendis Pharma A/S in the second quarter valued at about $4,931,000.

Ascendis Pharma A/S company profile

(Get a free report)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. Provides SKYTROFA to treat patients with growth hormone deficiency (GHD). The company is also developing a series of three independent endocrinology rare disease product candidates in clinical development, as well as focusing on advancing oncology therapeutic candidates.

See Also

Receive daily news and ratings for Ascendis Pharma A/S – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ascendis Pharma A/S and related companies with MarketBeat.com’s FREE daily email newsletter .